Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

  • التقارير
  • إصدار خط الأساس 2026
  • Complete edition

Exponential Technology Report 2026: Genomics and Gene Editing

The designed PDF, A4 or US Letter, is under Downloads below. To print this page instead, choose the paper in the print dialog. Review copies: the PDF with its DOI is issued at release.

Genomics and Gene Editing 2026

Imprint

المحرر
Saeed Valadbaygi, Chief Steward and Managing Editor, the Global Centre for Risk and Innovation (GCRI)
الناشر الرسمي
The Global Centre for Risk and Innovation (GCRI) for the Nexus Consortium, Toronto
Report number
NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE
إغلاق الأدلة
30 September 2026, cut DC-XTECH-GENOMICS-GLOBAL-2026-B0
الحالة
Draft under stewardship review; not yet released
DOI and UNI
Issued at deposit
الترخيص
CC BY 4.0 for Nexus-authored text, tables and figures; third-party material keeps its own licence
Cite as
Valadbaygi, S. (Ed.). (2026). Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI). https://therisk.global/nexus-reports/editions/xt-05/

المحتويات

  1. ·

    Executive summary

  2. 1

    Chapter 1. Genomics is data infrastructure and a therapeutic frontier

  3. 2

    Chapter 2. Key findings

  4. 3

    Chapter 3. Systems and sectors at baseline

  5. 4

    Chapter 4. Risks and capability

  6. 5

    Chapter 5. Individualised editing outpaces delivery systems

  7. 6

    Chapter 6. Readings from the other desks

  8. 7

    Chapter 7. The 2027 agenda

  9. 8

    Chapter 8. Systems in depth

  10. A

    Annex A. Methodology

  11. B

    Annex B. Data appendix

  12. C

    Annex C. References and record

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • طباعة

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF113 pages1.0 MBTagged, with bookmarks

      SHA-256 7276b0b0c2919661f94a296cdb60a579d1cb5466d3fab3011f46a9d5e81e42d6

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF123 pages1.0 MBTagged, with bookmarks

      SHA-256 da38a3579fdd5a3ac5c84f44a22853584be7e987208657578ede146f7b88fd58

  • Web edition

  • Data bundle

    • Indicators, CSV

      16 indicators with unit, year, status and source

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.csv1 KB

      SHA-256 f1c3fc5ae9f6823c263bb4a464c29a9516551ab806ef2a07fc3e737d1cd85a8d

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-indicators.json2 KB

      SHA-256 c54a918f9a805a488a8931ec6c1a235eb273361704df0909aae23d83048aa489

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-findings.csv3 KB

      SHA-256 0cb51833261dd188ca2af8a452aa38bbf651743f01a98776ff39430d07bcb97f

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 a09328c6428b83ba58eba3284cc50b50417b9fccd1c4d685a53746ed430fac83

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 95ff0d92b09d48fa348d982302647ab3ab0709cf5aaccccde30e735cade45a16

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 16aeb56c4b5eb0bfe8917c7848aec9209776f6cf7708280877069c0cfe0ef1f2

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Executive summary

The edition on a few pages: the abstract, the key messages, the headline finding and what each steward reads in it.

7 min read1 figure0 tables17 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

S.1Abstract

Genomics and gene editing matter to the Nexus programme in two ways. They are a data and hardware infrastructure: sequencers, reference genomes, biobanks, compute and a workforce that reads results. They are also a therapeutic technology whose first products are reaching patients, with rules that differ by country. The therapy evidence is strong for one product family. In a phase 3 study of exagamglogene autotemcel in sickle cell disease, 29 of 30 evaluable patients (97%) were free of severe vaso-occlusive crises for 12 months or more2. In transfusion-dependent beta-thalassaemia, 32 of 35 evaluable patients (91%) reached transfusion independence3. The FDA approved the first CRISPR-based therapy on 8 December 20231. A 2025 report describes one infant treated with a patient-specific base editor4. The data base is large. The first complete human genome sequence has 3.055 billion base pairs11, UK Biobank has sequenced 490,640 participants16, and the All of Us programme released 245,388 genomes, 77% from communities under-represented in research17. The physical and legal base is less measured. Vendor pages claim sequencing prices of USD 60 or more per genome15, independent costs are not bound, and compute has a carbon footprint21. Trade controls shaped sequencer supply in 20253031. Heritable editing is judged unacceptable at this time by the Third Summit28. This baseline sets out what the evidence supports and where it is thin. It forecasts no clinical or market outcome and ranks no country or company.

S.2Key messages

Six readings that frame the genomics baseline, and the eight questions this edition answers, each with its status and source.

  1. In two phase 3 studies most evaluable patients met the primary end point at short follow-up.23

    Do editing therapies work?Reported

  2. The FDA approved Casgevy on 8 December 2023 for patients 12 and older.1

    Is the approval real?Reported

  3. One infant received a patient-specific base editor in 2025; one case is not a trend.4

    Can a therapy be made for one patient?Reported

  4. No. A 2023 death after high-dose viral vector therapy and a 2025 liver event show open risks.910

    Is the safety record settled?Reported

  5. A complete genome of 3.055 billion base pairs and genome releases of 245,388 and 490,640 people.111617

    How large are the data resources?Reported

  6. Vendor pages claim list prices; independent cost data were not read.1415

    What does a genome cost?Reported

  7. The Third Summit judged it unacceptable at this time; national rules differ.2728

    What are the rules on heritable editing?Reported

  8. Whether delivery, payment and oversight can keep pace with individualised editing. SCN-XT05-DLV-01

    What will 2027 test first?Expert input

S.3Headline finding

ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-001

In a phase 3 study of exa-cel in severe sickle cell disease, 29 of 30 evaluable patients (97%) were free of severe vaso-occlusive crises for at least 12 consecutive months.

Figure S.1Evaluable patients in the sickle cell study (count)
البندBar, scaled to the largest valueالقيمة
Evaluable for the primary end point30
Free of severe crises for 12 months or more29
Free of related hospitalisation for 12 months or more30

Source: Frangoul et al., NEJM 20242. 44 patients received exa-cel; 30 had sufficient follow-up.

The result supports reading ex vivo editing of blood stem cells as a working therapy for one disease. Median follow-up was 19.3 months, patients needed myeloablative conditioning, and no cancers occurred in the period reported. The FDA approved the product on 8 December 2023 for patients 12 and older12.

S.4لمحة عامة

97%

sickle cell patients free of crises2

91%

thalassaemia patients transfusion independent3

3.055billion bp

complete genome sequence11

490,640participants

UK Biobank genomes16

245,388genomes

All of Us release17

42.9USD million

Casgevy revenue, Q1 20266

S.5What each steward reads in it

GCRI · KEY T

Technical Truth

The evidence supports reading genomics as data infrastructure and as a therapeutic technology.

GRF · KEY M

Public Meaning

For most people the genomics story arrives as a cure headline, a data-privacy scare or a price.

GRA · KEY F

Capital Meaning

Readiness implications only. Revenue is small, access depends on cost and manufacturing capacity, and one-time prices raise payment questions.

NEXUS

التوليف

Genomics is well described by single results and thinly measured as a system.

S.6What this edition is, and is not

What this edition is

A baseline: the 2026 state of genomics and gene editing as infrastructure and the couplings through which it carries risk into other systems. It synthesises published evidence and ranks no country, company or asset.

What it is not

Not a forecast of therapy uptake, a technology ranking, an endorsement of any vendor or an assessment of any programme. Clinical approval, data protection, trade controls and rules on heritable editing are decisions of competent authorities.

What comes next

National, regional and sector evidence feeds the 2027 genomics edition through the federation. Each edition reports what changed against this baseline: observations, source revisions, method changes, scenario updates and corrections.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  3. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  4. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  5. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  6. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  7. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  8. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  9. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  10. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  11. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  12. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back
  13. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  14. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03.back
  15. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  16. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  17. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back

Genomics is data infrastructure and a therapeutic frontier

Part I describes systems and their couplings. It ranks no country or operator and assesses no authority.

8 min read2 figures1 table22 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

1.1The questions this part answers

Key questions

  • Where is genomics risk concentrated?
  • Which couplings carry genomics shocks into other systems?
  • Which genomics capabilities hold under compound stress?
  • What must 2027 evidence measure first?

In this part

  • Narrative
  • Headline finding
  • Lead figure
  • Five footprint and governance chapters
  • Twelve-domain reading
  • Sector screens
  • Dependency matrix
  • Risk objects
  • Capability ladder
  • السيناريو
  • Three lenses
  • المحفظة

1.2The argument

Genomics is often told as a story of falling cost. The 2026 evidence reads it as two things at once: a data and hardware infrastructure of sequencers, reference genomes and biobanks, and a therapeutic technology whose first products now reach patients11161.

The therapy evidence is strong for one family. In two phase 3 studies, 97% of evaluable sickle cell patients and 91% of evaluable thalassaemia patients met the primary end point23. One infant received a patient-specific base editor in 20254. These are results at short follow-up, not a settled safety record910.

The data evidence is practical. A complete genome sequence of 3.055 billion base pairs exists11, a draft pangenome adds 119 million base pairs12, and two biobanks hold hundreds of thousands of genomes1617. Most genetic studies still rest on European ancestry1819.

The physical and legal base is the least measured part. Vendor pages claim low sequencing prices1415, the energy footprint of sequencing is unpublished, compute has a carbon footprint21, and trade rules changed sequencer supply in 20253031.

Figure 1.1How much sequence did the two reference releases add? Million base pairs

Both releases added sequence to the earlier reference. The two figures are measured against the same earlier reference but with different methods, so they are not additive1112.

البندBar, scaled to the largest valueالقيمة
T2T-CHM13 (2022): nearly 200 million base pairs of new sequence200
Draft pangenome (2023): 119 million base pairs of added polymorphic sequence119

Source: as cited in the note to this figure. Year 2023.

Figure ID FIG-XTECH-GENOMICS-GLOBAL-2026-BASELINE-01-003

3.055billion bp

T2T-CHM13 sequence, 202211

≈200million bp

new sequence in T2T-CHM1311

119million bp

added in the draft pangenome12

47assemblies

phased diploid assemblies in the draft pangenome12

1.3The six-sector nexus: twenty couplings across five assessed sectors

The genomics-centred matrix types the twenty couplings between the five core systems, read for their genomics content. Strengths are Nexus estimates (ESTIMATED) from the cited evidence and analogue events; they set the graph that 2027 evidence will test.

Figure 1.2Couplings across the six sectors

Each line is one coupling from one sector to another, drawn by the strength the edition assigns. Strengths are Nexus estimates from the cited evidence and analogue events. Infrastructure: not assessed in this edition’s coupling matrix, so it is drawn hollow with no couplings. The hexagon is the estate doctrine: six sectors and fifteen relations.

  • Strong
  • معتدلة
  • Weak
  • Not assessed in this edition

Source: this edition’s coupling matrix (Table 1.1); status Estimated. Hexagon: the estate doctrine (Signature).

Table 1.1Coupling matrix: from the row system to the column system
From, toWATENEFOOHLTBIO
WAT المياه·WEAK
no documented link
WEAK
no documented link
WEAK
no documented link
WEAK
no documented link
ENE الطاقةWEAK
no documented link
·WEAK
no documented link
WEAK
compute and cold chain power
WEAK
no documented link
FOO الغذاءWEAK
no documented link
WEAK
no documented link
·WEAK
no documented link
WEAK
no documented link
HLT الصحةWEAK
no documented link
WEAK
clinic and laboratory load
WEAK
no documented link
·MODERATE
genome data and therapy outcomes
BIO التنوع البيولوجيWEAK
no documented link
WEAK
no documented link
MODERATE
edited plants under new rules
MODERATE
genome variation and disease
·
Strength: strong, moderate or weak; a Nexus estimate (status Estimated) from cited evidence and analogue events. The scale is defined in Annex A.

Transmission paths

  1. 01

    DAT → HLT

    Reference genomes and biobanks inform diagnosis and therapy targets.

    Inferred T2T, UK Biobank and All of Us111617

  2. 02

    TRD → INF

    Trade rules change sequencer supply.

    Reported Illumina China bans and BIOSECURE3031

  3. 03

    FIN → HLT

    Payment and manufacturing capacity limit therapy access.

    Reported cost-effectiveness analysis and company report67

  4. 04

    ENE → INF

    Compute and cold chain power shape the cost of scale.

    Inferred carbon footprint studies2122

  5. 05

    GOV → HLT

    Approval pathways and heritable-editing limits set what reaches patients.

    Reported FDA and Third Summit1528

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  2. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  3. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  4. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  5. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  6. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  7. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  8. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03.back
  9. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  10. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  11. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03.back
  12. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03.back
  13. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  14. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  15. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  16. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  17. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  18. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  19. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  20. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back
  21. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  22. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back

Key findings

Twelve findings carry the genomics baseline. They are grouped by coupling and never ranked. Each resolves to its source or, where Nexus analysis is involved, to its stated method.

8 min read1 figure0 tables24 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

2.1Headline finding

ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-001

In a phase 3 study of exa-cel in severe sickle cell disease, 29 of 30 evaluable patients (97%) were free of severe vaso-occlusive crises for at least 12 consecutive months.

Figure 2.1Evaluable patients in the sickle cell study (count)
البندBar, scaled to the largest valueالقيمة
Evaluable for the primary end point30
Free of severe crises for 12 months or more29
Free of related hospitalisation for 12 months or more30

Source: Frangoul et al., NEJM 20242. 44 patients received exa-cel; 30 had sufficient follow-up.

Implication

The result supports reading ex vivo editing of blood stem cells as a working therapy for one disease. Median follow-up was 19.3 months, patients needed myeloablative conditioning, and no cancers occurred in the period reported. The FDA approved the product on 8 December 2023 for patients 12 and older12.

What would move it

Longer follow-up, treatment counts, price negotiations and cost-effectiveness studies would each move this finding67.

2.2الصحة

  1. ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-001

    In a phase 3 study of exa-cel in severe sickle cell disease, 29 of 30 evaluable patients (97%) were free of severe vaso-occlusive crises for 12 months or more, and all 30 were free of related hospitalisation.2

  2. ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-002

    In a phase 3 study of exa-cel in transfusion-dependent beta-thalassaemia, 32 of 35 evaluable patients (91%) reached transfusion independence for 12 months or more.3

  3. ReportedEQL 3NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-003

    A 2025 report describes one infant with carbamoyl-phosphate synthetase 1 deficiency who received a patient-specific base-editing therapy in two infusions; follow-up was 7 weeks after the first infusion and no serious adverse events occurred.45

  4. ReportedEQL 2NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-HLT-004

    In October 2025 a patient in a phase 3 trial of an in vivo editing therapy had a life-threatening liver event, and the FDA placed two trials on hold, according to trade press reporting company disclosures.939

2.3المالية

  1. ReportedEQL 3NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-FIN-005

    Casgevy revenue was USD 42.9 million in the first quarter of 2026 against USD 14.2 million a year earlier, and a cost-effectiveness analysis states that gene therapy access is limited by cost and manufacturing capacity.67

2.4Data and digital

  1. ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-DAT-006

    The T2T-CHM13 sequence has 3.055 billion base pairs with nearly 200 million new, and the draft pangenome holds 47 phased diploid assemblies and adds 119 million base pairs of polymorphic sequence.1112

  2. ReportedEQL 4NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-DAT-007

    UK Biobank released whole genomes for 490,640 participants and All of Us released 245,388 genomes, of which 77% are from communities under-represented in research; literature finds most studies still rest on European ancestry.16171819

2.5البنية التحتية

  1. ReportedEQL 2NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-INF-008

    Vendor pages claim more than 128 genomes per run on one sequencer and a USD 60 genome at list price on another; neither claim is independent evidence.141540

2.6الطاقة

  1. ReportedEQL 3NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-ENE-009

    A study of common analyses found biobank-scale association studies emit substantial carbon, and a software upgrade cut one tool footprint by 73%.2122

2.7التجارة

  1. ReportedEQL 3NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-TRD-010

    China listed Illumina as an unreliable entity in February 2025, banned its sequencer imports in March 2025 and lifted the ban on 10 November 2025; the BIOSECURE Act was enacted on 18 December 2025.3031

2.8الحوكمة

  1. ReportedEQL 5NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-GOV-011

    The FDA approved Casgevy and Lyfgenia on 8 December 2023, and the Third Summit organising committee judged heritable genome editing unacceptable at this time on 8 March 2023.12728

2.9النظمي

  1. Expert inputEQL 2NRF-XTECH-GENOMICS-GLOBAL-2026-BASELINE-SYS-012

    The leading compound pathway for 2027 testing is individualised editing moving faster than the payment, manufacturing and oversight systems around it. § scenario

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  3. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  4. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  5. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  6. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  7. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  8. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  9. 39Intellia Therapeutics, Inc. (ed.), Form 8-K of 27 January 2026 and Form 8-K exhibit 99.2 of 2 March 2026 (company filings read; the FDA imposed clinical holds on the MAGNITUDE and MAGNITUDE-2 trials on 29 October 2025 and removed them on 27 January 2026 for MAGNITUDE-2 and on 2 March 2026 for MAGNITUDE, with enhanced liver monitoring; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-05.back
  10. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  11. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  12. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  13. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  14. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03.back
  15. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03.back
  16. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  17. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  18. 40Ultima Genomics (ed.), Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris (press release, 24 February 2025, read through a wire copy; USD 0.24 per million reads, enabling the USD 80 genome; vendor evidence, weak). Ultima Genomics, Fremont. Observation year 2025. Accessed 2026-11-05.back
  19. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  20. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back
  21. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  22. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  23. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  24. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back

Systems and sectors at baseline

6 min read0 figures2 tables16 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

3.1Where each system stood at evidence close

HLT · Therapy

Evaluable sickle cell patients free of severe crises

97%

29 of 30 patients, 12 months or more.

مُبلَّغ عنه2024NEJM2

DAT · Reference

Base pairs in the complete T2T-CHM13 sequence

3.055billion

nearly 200 million base pairs new.

مُبلَّغ عنه2022العلم11

DAT · Biobanks

Participants with whole genomes in UK Biobank

490,640participants

released in 2025.

مُبلَّغ عنه2025الطبيعة16

FIN · Finance

Casgevy revenue in the first quarter

42.9USD million

against 14.2 in the first quarter of 2025; company report.

Reported2026Vertex6

INF · Hardware

Vendor claim: genomes per NovaSeq X Plus run

>128genomes

vendor page, not independent evidence.

Reported2026Illumina14

TRD · Trade

Fall in Illumina instrument sales in China, third quarter

54% fall

year on year; import ban lifted in November 2025.

Reported2025MedTech Dive31

3.2Domain posture

Each of the twelve coupled domains is read through genomics, in words, not scored. The coupling column names the dependency that carries genomics risk into each domain.

Table 3.1Each domain read in words, not scored
المجالPosture at baselineالترابطالحالة
WATWater use of sequencing laboratories and cell-therapy manufacture is not published.none documentedExpert input EQL 1
ENECompute for genomics has a carbon footprint; sequencing and cold-chain energy is unpublished.ENE ↔ INFReported EQL 3
FOOGene-edited plants are regulated in England and the EU; yield and uptake evidence is not bound here.GOV → FOOReported EQL 3
HLTThe core therapeutic coupling: one approved editing product, a case report and safety events.the core systemReported EQL 4
BIOReference genomes and pangenomes describe human variation; ecological applications are not evidenced here.DAT → BIOReported EQL 3
CLIFootprint at scale is not bound; no figure is used.ENE → CLIExpert input EQL 1
INFSequencers, flow cells and cold chains carry the work; throughput claims come from vendors.INF ↔ DATReported EQL 2
FINCasgevy revenue is rising from a small base; access is limited by cost and manufacturing capacity.FIN → HLTReported EQL 3
DATReference genomes and two large biobanks; ancestry balance is uneven.the data carrierReported EQL 4
AICA genome foundation model trained on 9.3 trillion base pairs was reported in a 2025 preprint; clinical use is not evidenced here.DAT → AICReported EQL 2
MINNo documented mineral coupling at baseline; consumables and reagents are not assessed.none documentedExpert input EQL 1
TRDTrade rules changed instrument supply in 2025 and a procurement law followed.TRD → INFReported EQL 3

3.3Sector screens

All sixteen sectors are screened for their dependence on genomics, on the same grammar as every national edition. The evidence column describes coverage of the baseline evidence, not the performance of the sector.

Table 3.2Sectors: baseline evidence and the exposure to watch
الرمزالقطاعBaseline evidenceExposure to watchEvidence coverage
GS-00Cross-systemgenomics couples to health, data, trade and financedelivery outpaces oversightTHIN
GS-01المياهwater use not publishednone documentedTHIN
GS-02الطاقةcompute footprint21load from large computeTHIN
GS-03الغذاءplant editing rules2936regulatory divergencePARTIAL
GS-04الصحةapproved therapy and phase 3 results123safety and accessGOOD
GS-05الماليةCasgevy revenue6payment of one-time therapiesPARTIAL
GS-06التطويرcost barrier in low-income settings8widening gapsTHIN
GS-07المناخfootprint at scale not boundenergy demandTHIN
GS-08يدرس مجالno documented couplingnone documentedTHIN
GS-09البنية التحتيةsequencer and cold-chain needs14single-vendor dependenceTHIN
GS-10المدنno documented couplingnone documentedTHIN
GS-11التنوع البيولوجيno documented couplingnone documentedTHIN
GS-12رصد الأرضno documented couplingnone documentedTHIN
GS-13المجال السيبراني والرقميgenetic data sale in bankruptcy3238data protectionPARTIAL
GS-14السياساتWHO framework and national rules272936uneven oversightPARTIAL
GS-15العلمstrong peer-reviewed base21112common benchmarksGOOD

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  3. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  4. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  5. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  6. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  7. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  8. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
  9. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  10. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  11. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  12. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back
  13. 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  14. 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05.back
  15. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  16. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back

Risks and capability

Four genomics risk objects open the portfolio. Order carries no rank. Each is read across driver, exposure, vulnerability, capacity, cascade and consequence.

8 min read0 figures1 table27 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

4.1Risk objects

Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.

  1. InferredEQL 3RSK-XT05-HLT-001

    Safety events in in vivo editing

    المحرك
    high-dose delivery and new targets910
    التعرّض
    patients in early trials
    قابلية التأثر
    small trials; short follow-up
    القدرة
    clinical holds, monitoring and review927
    التسلسل المتتالي
    HLT → FIN, GOV
    الأفق
    1 to 5 years
  2. InferredEQL 3RSK-XT05-DAT-002

    Genetic data ownership and privacy

    المحرك
    sale of a large genetic database in bankruptcy3238
    التعرّض
    millions of customers
    قابلية التأثر
    consent and state-by-state rules; weak federal limits
    القدرة
    state privacy laws and non-discrimination law44
    التسلسل المتتالي
    DAT → FIN, HLT
    الأفق
    1 to 5 years
  3. InferredEQL 3RSK-XT05-TRD-003

    Sequencer and consumable supply politics

    المحرك
    trade controls and procurement law3031
    التعرّض
    laboratories relying on one instrument family
    قابلية التأثر
    few suppliers; reagent supply not assessed
    القدرة
    new entrants and alternative platforms15
    التسلسل المتتالي
    TRD → INF → DAT
    الأفق
    1 to 5 years
  4. InferredEQL 3RSK-XT05-GOV-004

    Uneven oversight of editing

    المحرك
    differing national rules and a fast-moving bespoke pathway52936
    التعرّض
    cross-border treatment and research
    قابلية التأثر
    heritable-editing rules differ; some rely on soft law284142
    القدرة
    WHO framework and summit statements2728
    التسلسل المتتالي
    GOV → HLT, FIN
    الأفق
    1 to 10 years

4.2Capability ladder

Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for genomics at the global level.

Table 4.1Capabilities on the ladder of evidence: listed, exists, demonstrated, tested
الوظيفةRungالمستوىStrongest public evidence at baseline
Prevention and mitigationEXISTSnewborn and population screening programmes running34
Monitoring and observationLISTEDno common tracker of treatment counts or long-term safety
الإنذار المبكرLISTEDsafety signals reach the public through company disclosures9
Preparedness and planningEXISTSWHO framework and approval pathways1527
Redundancy and reservesLISTEDinstrument and reagent reserves are not documented
الاستجابةEXISTSclinical holds and monitoring rules were applied in 20259
Continuity of critical servicesLISTEDcold-chain continuity for cell therapies not documented
التعافيLISTEDnot applicable at baseline
AdaptationEXISTSnew pathways for individualised therapies are being drafted537
الحماية الاجتماعيةLISTEDaccess in low-income settings is limited8
التمويل والتأمينLISTEDprice negotiations ongoing; payer data not bound7
Institutional coordinationEXISTSsummits and WHO governance work2728
Technical infrastructureEXISTSreference genomes and biobanks available111617
WorkforceLISTEDgenetic counsellor numbers known; wider workforce not bound33
Research capacityADEQUATEstrong peer-reviewed base2111224
A capability listed in policy is not a tested one; each rung is the strongest public evidence at baseline.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  2. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03.back
  3. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  4. 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  5. 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05.back
  6. 44United States Congress (ed.), Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 122 Stat. 881, 21 May 2008 (enrolled text read; prohibits discrimination on the basis of genetic information in health insurance and employment). US Government Publishing Office, Washington. Observation year 2008. Accessed 2026-11-05.back
  7. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  8. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  9. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  10. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  11. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
  12. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  13. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back
  14. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05.back
  15. 42Lander, E.S. et al., Adopt a moratorium on heritable genome editing, Nature 567 (7747), 165 to 168, 2019 (record read via Crossref). Springer Nature, London. Observation year 2019. Accessed 2026-11-05.back
  16. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
  17. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  18. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05.back
  19. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back
  20. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  21. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  22. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  23. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  24. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  25. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  26. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  27. 24Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 2012 (abstract read through the Europe PMC record). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-03.back

Individualised editing outpaces delivery systems

A conditional statement under stated assumptions, never a prediction.

2 min read0 figures0 tables3 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

5.1الافتراضات

Scenario SCN-XT05-DLV-01: what is assumed, and what is held constant.

خط الأساس
the 2026 reference state in this edition
الدوافع
bespoke editing pathways open faster than payment, manufacturing and oversight capacity grow
Analogues
the 2025 patient-specific therapy and the 2025 trial holds459
Interventions
none modelled: the specification describes the unmitigated case
Run state
narrative specification; quantified run scheduled for 2027

5.2The cascade, step by step

  1. 1

    GOV → HLT

    a plausible mechanism pathway lowers the evidence needed for bespoke therapies

    2025

  2. 2

    HLT → FIN

    payers face one-time prices with thin outcome data

    2026

  3. 3

    INF → HLT

    manufacturing and clinic capacity limit who is treated

    2026

  4. 4

    HLT → GOV

    a safety event in a bespoke or in vivo therapy triggers holds

    2025

  5. 5

    TRD → INF

    trade rules change instrument and reagent supply

    2025

  6. 6

    DAT → FIN

    genetic data and biobanks become assets in disputes over ownership

    2025

5.3The scenario as a table of steps

How the shock in scenario SCN-XT05-DLV-01 would travel through Genomics and Gene Editing’s coupled systems, step by step, under the assumptions the edition states.

خطوةما يحدثالمصدر
01 Governance to healthA plausible mechanism pathway lowers the evidence needed for bespoke therapies. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 1
02 Health to financePayers face one-time prices with thin outcome data. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 2
03 Infrastructure to healthManufacturing and clinic capacity limit who is treated. Analogue or source: 2026.Edition XT-05, scenario SCN-XT05-DLV-01, step 3
04 Health to governanceA safety event in a bespoke or in vivo therapy triggers holds. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 4
05 Trade to infrastructureTrade rules change instrument and reagent supply. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 5
06 DAT to financeGenetic data and biobanks become assets in disputes over ownership. Analogue or source: 2025.Edition XT-05, scenario SCN-XT05-DLV-01, step 6

A teaching model of a conditional scenario under the edition’s stated assumptions: not a forecast, not a prediction and not a warning. Sources: Genomics and Gene Editing 2026, scenario SCN-XT05-DLV-01 (2026); Genomics and Gene Editing 2026, references (NR-CIT-1) (2026).

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  2. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  3. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back

Readings from the other desks

The genomics baseline is read through each steward’s lens, then once as a whole. Each lens is a projection of reviewed findings, not a separate argument. The other desks’ own editions of this subject are listed first, as cross-references, not copies.

15 min read0 figures8 tables36 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

6.1The other desks’ editions of this subject

Federation: each desk writes its own edition for the subjects in its remit. Until a desk releases, its edition shows its frame and the reading this edition printed for it.

المكتبالطبعةالحالةالمعرّف
GCRI Systems EvidenceSystems Evidence: Genomics and Gene Editing 2026Drafted, in stewardship reviewNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
GRF Public DeliberationOutside this desk’s remitNot in remit
GRA Capital ReadinessOutside this desk’s remitNot in remit
Standards ProgressStandards Progress: Genomics and Gene Editing 2026قيد الإعدادNR-NXS-XT-05-2026-BASELINE (reserved)
Academy CapabilityCapability: Genomics and Gene Editing 2026قيد الإعدادNR-RA-XT-05-2026-BASELINE (reserved)
Index MeasurementOutside this desk’s remitNot in remit

6.2Three lenses

One edition, read by each steward. The lens of this site comes first.

GCRI · KEY T

Technical Truth

The evidence supports reading genomics as data infrastructure and as a therapeutic technology. Results are strong for one therapy family and for reference data, and the physical, cost and supply layers are thinly measured. Evidence is strongest for single peer-reviewed results, and weakest for energy, cost and treatment counts.

HLT-001 · DAT-006 · GOV-011 · SYS-012

GRF · KEY M

Public Meaning

For most people the genomics story arrives as a cure headline, a data-privacy scare or a price. The baseline asks that public debate separate peer-reviewed results from company claims, and keep consent over genetic data in view.

HLT-001 · HLT-004 · DAT-007

GRA · KEY F

Capital Meaning

Readiness implications only. Revenue is small, access depends on cost and manufacturing capacity, and one-time prices raise payment questions67. These show where finance-readiness evidence will matter. Nothing here is advice, a rating or an approval.

FIN-005 · HLT-002

NEXUS

التوليف

Genomics is well described by single results and thinly measured as a system. The 2027 programme should count treatments, publish a comparable footprint and test the delivery pathway before more bespoke therapies reach patients.

SYS-012 · Q-01 · Q-02

6.3Standards, Academy and steward contributions

How the Nexus Standards drafts, the Risk Academy and the three stewards feed each quarterly edition for genomics. The standards are a preparatory working draft (2026) and are cited as drafts, never as adopted standards.

Table 6.1The quarterly rhythm every edition follows
Quarterالطبعةالسؤالالحدود
Q1State and Agendaما المهم هذا العام، وما وضع الانطلاق؟observed baseline stays distinct from planned work
Q2Evidence and BuildWhat new evidence and capability exist?a configured capability is not a validated result
Q3Stress Test and ReadinessWhat do scenarios and tests show?simulated loss or performance is not observed impact
Q4Annual Synthesis and RenewalWhat changed in the year, and what renews?release follows review, not event publicity deadlines
Table 6.2Who contributes what each quarter
Steward or bodyالدورContribution route
⁨GCRI Canada⁩Lead Institution and Consortium Secretariat; publisher of record; technical truth (key T)science and practice communities · GCRI gateway
The ⁨Global Risks Forum⁩ (⁨GRF⁩)leadership, dialogue and the Universe programme; public meaning (key M)policy, Universe and national adoption · GRF gateway
The ⁨Global Risks Alliance⁩ (⁨GRA⁩)finance, insurance and development readiness; capital meaning (key F)finance and insurance · GRA gateway
⁨Nexus Standards⁩preparatory drafts on vocabulary, hazards, indicators and methodsStandards site · working groups HAZ, IND, MTH, FIN, AI
⁨Risk Academy⁩learning pathways tied to the agenda questionsAcademy gateway · learning by review
Nexus Standards and Academytechnology chapter inputs: GCRI evidence, NXS standards, RA capabilitytechnology editorial board

Standards drafts used in this edition

  • Risk vocabulary NRS-C1 (424 terms) for terms in the glossary
  • Hazard atlas NHS-1 1.1.0 (905 hazards in 120 families) for risk objects
  • Seven risk classes: global, catastrophic, existential, emerging, planetary, exponential, frontier-tech

Standards calendar to watch

  • Founding calls from 20 October 2026; working groups meet from 5 November 2026
  • Inaugural Global Standards Council session, 12 January 2027
  • Quarterly reviews in March, June, September and December, aligned with each edition

6.4GCRI reading: the model card

GCRI’s reading of this edition is its model card: what the national model is, what it computes and where it stops. It is printed in full in Annex A, with the methods it belongs to. Annex A, methodology

6.5Global Risks Forum reading: editorial essays

Four signed essays by the Reports editorial team set out the positions this edition takes. They are interpretation, labelled as such; the evidence they draw on is in the findings register.

Genomics is a data and hardware build-out and a therapeutic frontier. The first is large and measurable; the second is real for one product family and early for the rest. Keeping them apart avoids both hype and complacency.

EDITORIAL ESSAY · 01

Two stories, one technology

A peer-reviewed phase 3 report, a company revenue line and a vendor price page carry different weight. This edition labels each and asks for a common basis before costs are compared.

EDITORIAL ESSAY · 02

Separate results, claims and prices

Compute, cold chains and instruments are rarely counted. A published footprint would show whether scale is limited by energy, supply or money.

EDITORIAL ESSAY · 03

The footprint is the blind spot

Therapies exist for a few patients. Whether they reach people in low-income settings depends on cost, manufacturing and clinics, which analyses are only starting to model.

EDITORIAL ESSAY · 04

Access is the open question

6.6Global Risks Alliance reading: 2027 genomics readiness pack

The registers that open the 2027 global cycle. At baseline each is initialised from this edition.

Table 6.32027 genomics readiness pack
البندسجّلState at baselineFirst 2027 entry
E1Genomics risk state deltabaseline set by this editionchanges against the baseline
E2WEFH+B state deltafive global system readings setindicator updates and freshness
E3Agenda and Portfolio movementeight agenda items · 6 proposed objectsadmission decisions
E4Federation delivery registernational chapters in preparationnational chapters
E5Consortium capability registernational consortia formingfirst contributions
E6Leadership questions and challengesلا شيء بعدfirst challenge log
E7Foundry technical statenational environments preparedfirst federation cut
E8Publication candidatestwelve findings carried forwardPUBLISH · HOLD dispositions
E9Universe readinessone candidate missionadmission and role spine
E10Correction registerلا شيءfirst federation-wide cycle

Publication dispositions

  • النشر
  • Hold
  • Needs evidence
  • مقيَّد
  • مُستبدَل

6.7Nexus Standards reading: standards and regulatory watch

Instruments and published guidance that shape the systems in this edition, by status on the retrieval date. The edition assesses no one’s compliance.

  • IN FORCE
  • PUBLISHED
  • DRAFT
  • PUBLISHED · VOLUNTARY
Table 6.4Standards and regulatory watch
الأداةالهيئةالنطاقالحالةالصلة
FDA approval of Casgevy and Lyfgenia1FDAUSPUBLISHED 2023approval
Plausible mechanism pathway537FDAUSDRAFT 2026bespoke therapies
Human genome editing framework27WHOglobalPUBLISHED · VOLUNTARYgovernance
Third Summit statement28organising committeeglobalPUBLISHED 2023heritable editing
Genetic Technology (Precision Breeding) Act 202329UK ParliamentإنكلتراIN FORCEplant editing
Regulation (EU) 2026/138836EU Parliament and CouncilEUPUBLISHED 2026plant editing
BIOSECURE provisions in the FY2026 NDAA30US CongressUSIN FORCEprocurement
Oviedo Convention41مجلس أوروباأوروباIN FORCEgenome interventions
Genetic Information Nondiscrimination Act44US CongressUSIN FORCEdata and employment
Heritable editing moratorium call42scientistsglobalPUBLISHED 2019moratorium

Changed since 2024

  • The EU adopted its regulation on plants from new genomic techniques in June 2026, to apply from July 202836
  • The FDA described a plausible mechanism pathway and issued draft guidance in 2026537
  • The BIOSECURE provisions were enacted on 18 December 202530

To watch in 2027

  • The OMB list of biotechnology companies of concern due by 18 December 202630
  • Final FDA guidance on the plausible mechanism pathway37
  • Application of the EU regulation on new genomic techniques from 202836

6.8Risk Academy reading: literature and evidence review, science and assessments

The review behind this edition covers genomics assessments, peer-reviewed science and the institutional reports that bind its findings. Systematic reviews for each agenda item begin in 2027.

Review protocol

السؤال
What does the published evidence establish about genomics and gene editing as infrastructure and its couplings?
Sources searched
peer-reviewed journals and preprints; regulators and international bodies; statutes and statements; market, vendor and trade-press reports
النافذة
releases available at evidence close, 30 September 2026
الاختيار
sources that bind or contextualise a finding in this edition
الخطوة التالية
systematic reviews for agenda items 01 to 05 in 2027
Table 6.5Peer-reviewed science and preprints
المرجعالنوعالسنةالدورUsed for
Frangoul et al.2journal article2024supportssickle cell therapy
Locatelli et al.3journal article2024supportsthalassaemia therapy
Musunuru et al.4journal article2025supportspatient-specific editing
Lek et al.10journal article2023contextsafety event
Nurk et al.11journal article2022supportscomplete genome
Liao et al.12journal article2023supportspangenome
Jinek et al.24journal article2012frameworkprogrammable Cas9
Komor et al.25journal article2016frameworkbase editing
Table 6.6Clinical evidence and safety
المرجعIssuerالسنةالدورUsed for
Anzalone et al.26journal article2019frameworkprime editing
UK Biobank consortium16journal article2025supportswhole genomes
All of Us investigators17journal article2024supportsdiverse cohort
Fatumo et al.18journal article2022contextdiversity roadmap
Sirugo, Williams and Tishkoff19journal article2019contextmissing diversity
Stephens et al.20journal article2015contextdata growth
IHGSC43journal article2001frameworkfirst draft sequence
Grealey et al.21journal article2022supportscompute footprint
Table 6.7Standards, policy and governance
المرجعIssuerالسنةالدورUsed for
FDA approval notice1FDA2023supportsapproval
WHO framework27WHO2021supportsgovernance
Third Summit statement28organising committee2023supportsheritable editing
Precision Breeding Act29UK Parliament2023supportsplant editing
Oviedo Convention41مجلس أوروبا1997contextgenome interventions
Table 6.8Supply, market and data overviews
المرجعIssuerالسنةالدورUsed for
Vertex first quarter report6Vertex2026contextcompany revenue
Cost-effectiveness analysis7Blood2026supportscost and capacity
Illumina product page14Illumina2026contextvendor claim
Ultima product page15Ultima2026contextvendor claim
Employment projection33BLS2025supportsworkforce
Generation Study34Genomics England2026contextnewborn sequencing
Evo 2 preprint23bioRxiv2025contextgenome model

Where the evidence agrees

  • Ex vivo editing met its primary end point in most evaluable patients at short follow-up23
  • Genomic datasets are large and still weighted to European ancestry16171819
  • Heritable editing is not currently acceptable28

Where it is unsettled

  • Long-term safety of in vivo editing and high-dose delivery910
  • Real sequencing and therapy costs on a common basis1415
  • How much energy and cooling genomics needs at scale2122

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  2. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  3. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  4. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  5. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05.back
  6. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  7. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back
  8. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
  9. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  10. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  11. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05.back
  12. 44United States Congress (ed.), Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 122 Stat. 881, 21 May 2008 (enrolled text read; prohibits discrimination on the basis of genetic information in health insurance and employment). US Government Publishing Office, Washington. Observation year 2008. Accessed 2026-11-05.back
  13. 42Lander, E.S. et al., Adopt a moratorium on heritable genome editing, Nature 567 (7747), 165 to 168, 2019 (record read via Crossref). Springer Nature, London. Observation year 2019. Accessed 2026-11-05.back
  14. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  15. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  16. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
  17. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03.back
  18. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  19. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  20. 24Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 2012 (abstract read through the Europe PMC record). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-03.back
  21. 25Komor, A.C. et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature 2016 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2016. Accessed 2026-11-03.back
  22. 26Anzalone, A.V. et al., Search-and-replace genome editing without double-strand breaks or donor DNA, Nature 2019 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
  23. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  24. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  25. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03.back
  26. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03.back
  27. 20Stephens, Z.D. et al., Big Data: Astronomical or Genomical?, PLOS Biology 2015 (abstract read through the Europe PMC record). Public Library of Science, San Francisco. Observation year 2015. Accessed 2026-11-03.back
  28. 43International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 409 (6822), 860 to 921, 2001 (record read via Crossref). Springer Nature, London. Observation year 2001. Accessed 2026-11-05.back
  29. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  30. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  31. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  32. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  33. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
  34. 23Brixi, G. et al., Genome modelling and design across all domains of life with Evo 2, bioRxiv preprint 2025 (abstract read through the Europe PMC record; trained on 9.3 trillion base pairs; not peer reviewed at the time of reading). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03.back
  35. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  36. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back

The 2027 agenda

Eight bounded questions open the 2027 genomics agenda. Each comes from a baseline finding, names the initiative that will carry it and the first output due in the 2027 genomics edition.

5 min read0 figures6 tables5 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

7.1Questions for the operational series

  1. Q-01

    How many patients are treated with editing therapies, at what price, and where are the access gaps?

    INI-XT05-DLV-01 · delivery and access; first output: treatment and price register.

  2. Q-02

    What energy, cooling and cold-chain load do sequencing and cell therapies carry?

    INI-XT05-ENE-02 · footprint of genomics; first output: footprint estimates by activity.

  3. Q-03

    What do sequencing and therapy costs look like on an independent basis?

    INI-XT05-CST-03 · cost on a common basis; first output: cost table.

  4. Q-04

    Which instruments, consumables and reagents are single points of failure?

    INI-XT05-SUP-04 · sequencer supply; first output: dependence map.

  5. Q-05

    How balanced are genome datasets by ancestry on a common basis?

    INI-XT05-DIV-05 · dataset balance; first output: ancestry table.

  6. Q-06

    Which national rules cover genetic data, somatic editing and heritable editing?

    To be admitted in 2027; first output: rule overlay.

  7. Q-07

    What workforce exists for genetic counselling, laboratory work and bioinformatics?

    To be admitted in 2027; first output: scoping note.

  8. Q-08

    Which readiness capabilities have been tested, and which are only planned?

    Readiness capability register; first output: rung evidence for 15 functions.

7.2Portfolio proposed for the Q1 2027 alignment

Five initiatives and one Universe mission candidate are proposed for the 2027 genomics portfolio. They are programme objects: no partner, funder or member is attached to them in this edition.

Table 7.1Objects proposed for the first operational quarter
IDالكائنالنوعالسؤالالحالة
INI-XT05-DLV-01Delivery and accessInitiativeQ-01مقترح
INI-XT05-ENE-02Footprint of genomicsInitiativeQ-02مقترح
INI-XT05-CST-03Cost on a common basisInitiativeQ-03مقترح
INI-XT05-SUP-04Sequencer supplyInitiativeQ-04مقترح
INI-XT05-DIV-05Dataset balanceInitiativeQ-05مقترح
MSN-XT05-2027-01Delivery pathway Universe missionالرسالةQ-01Candidate

7.3The pathway

The genomics edition reads national readiness chapters, the coupled sector reports on health and data, and the global edition through one governed evidence graph. At baseline the federation is designed; the global energy and lifeline editions are drafted. This page states what exists today and what comes next.

  1. 01

    National readiness chapters

    genomic medicine and data-protection readiness in each national edition

    IN PREPARATION · national baselines

  2. 02

    Sector couplings

    GS-04 health · XT-04 biotechnology · XT-10 cryptography

    GS-04 DRAFTED · sector baselines

  3. 03

    Technology system model

    sequencing, data, therapies, trade, workforce, governance

    v0 SPECIFIED · v1 with federation evidence

  4. 04

    Strategic links

    SR-02 lifeline systems · SR-13 strategic technology

    PLANNED · strategic baselines

  5. 05

    ⁨Universe⁩

    annual proving environment

    CANDIDATE MISSION · mandate in 2027

  6. 06

    XT-05 report

    this series

    BASELINE DRAFT · 2027 annual edition

  7. 07

    Evidence and correction

    one graph, many projections

    OPEN · first correction cycle in 2027

7.4Universe 2027: evidence pack for the genomics candidate mission

  1. 01

    التفويض

  2. 02

    Core Build · 1 month

  3. 03

    Action · 1 week

  4. 04

    Evidence seal

  5. 05

    Portfolio correction

  6. 06

    Next mandate

Table 7.2Universe 2027: evidence pack for the genomics candidate mission
البندالتسجيلالحالةالتوقيت
F1Annual mandate recordPLANNEDafter the Q2 2027 alignment
F2Core Build recordPLANNEDone month before the exercise
F3أدلة التمارينPLANNEDduring the Action week
F4Decision packetsPLANNEDexercise state only
F5Proof receiptsPLANNEDscoped to each recorded check
F6After-action reportPLANNEDwithin one quarter
F7Upgrade docketPLANNEDrouted to the Portfolio
F8Portfolio renewalPLANNED2027 global annual edition
F9Public synthesisPLANNEDpublic-safe extracts only

الرسالة

ID
MSN-XT05-2027-01 · Delivery pathway Universe mission
Role spine
Leadership sponsor · Institutional anchor · Mission lead: drawn from national pathways
Receiving actors
to be identified with the mandate

7.5Handoffs and routing

Where the baseline’s findings go next. A handoff routes a finding for awareness, review or work; it transfers no authority.

Table 7.3Handoffs and routing
النتيجةRouted toالغرضالفئة
HLT-001 · sickle cell therapyINI-XT05-DLV-01delivery and accessPUBLIC
HLT-004 · safety eventINI-XT05-DLV-01delivery and accessPUBLIC
DAT-007 · biobanksINI-XT05-DIV-05dataset balancePUBLIC
INF-008 · vendor claimsINI-XT05-CST-03cost on a common basisPUBLIC
ENE-009 · compute footprintINI-XT05-ENE-02 · key F reviewfootprint of genomicsPUBLIC
TRD-010 · tradeINI-XT05-SUP-04sequencer supplyPUBLIC
GOV-011 · approval and governanceregional consortiarule overlayPUBLIC
SYS-012 · compound pathwayMSN-XT05-2027-01Universe candidateCONSORTIUM
Table 7.4Routing rules by publication class
الفئةWhere it goesWho can see it
PUBLICthe published edition and its evidence bundleanyone
CONSORTIUMgoverned rooms of the federationconsortium members under agreement
CONTROLLEDneed-to-know channelsnamed competent actors only

7.6Feeds and signal register

Table 7.5Feeds watched from 2027
FeedProducerLatencyFeeds into
Journals and preprints on editing and safetypeer review and preprintsمستمرHLT-001
FDA approvals and guidanceFDAلكل إصدارGOV-011
Biobank data releasesbiobanksلكل إصدارDAT-007
Company results and announcementscompaniesفصليFIN-005
Trade and procurement noticesagencies and ministriesلكل حدثTRD-010
Employment projectionsBLSسنويFIN-005
Clinical hold and safety noticescompanies and FDAلكل حدثHLT-004

Escalation routes

  • none · keep monitoring
  • research question
  • project
  • risk object
  • annual publication
  • signal report
Table 7.6Signals at baseline
IDSignalCorroborationالنظمالمسار
SIG-XT05-001Phase 3 exa-cel results23CORROBORATEDHLTresearch question Q-01
SIG-XT05-002Clinical hold on in vivo editing trials, October 20259PARTIALHLTresearch question Q-01
SIG-XT05-003Vendor price claims for sequencing1415PARTIALINFinitiative Q-03

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  3. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  4. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  5. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back

Systems in depth

One section per system: its state at evidence close, its exposures and what the operational series will watch.

9 min read0 figures5 tables25 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

8.1Sequencing hardware, data and compute

Sequencers, reference genomes and biobanks carry the data base. Evidence is strongest where peer review exists, and weakest where claims rest on vendor pages.

3.055billion bp

T2T-CHM13 complete sequence11

490,640participants

UK Biobank whole genomes16

>128genomes

vendor claim per NovaSeq X Plus run14

Table 8.1State at baseline
المكوّنالحالةالأدلةالحالة
Reference genomesa complete sequence and a 47-assembly draft pangenome published1112مُبلَّغ عنه
Biobankstwo releases of 490,640 and 245,388 genomes1617مُبلَّغ عنه
Sequencersvendor pages claim 16 to 21 Tb per run and a USD 60 genome on another platform1415مُبلَّغ عنه
Genome modelsa 2025 preprint reports a model trained on 9.3 trillion base pairs23مُبلَّغ عنه

الاقترانات

  • INF ↔ DAT hardware and data
  • DAT → HLT diagnosis and targets
  • DAT → AIC genome models

Evidence to bind in 2027

  • independent cost per genome
  • sequencer fleet by country

Related editions

  • GLB Global Systems
  • GS-04 Health
  • XT-04 Biotechnology
  • XT-10 Cybersecurity and Advanced Cryptography
  • SR-04 Critical Minerals and Strategic Materials
  • XT-01 Artificial Intelligence and Agentic Systems

8.2Compute, energy and cold chains

Genomics is a big-data science, and compute has a carbon footprint. The energy and cooling use of sequencing and of cell-therapy cold chains is not published.

73%

cut in one tool footprint after a software upgrade21

2025projection year

genomics compared with astronomy and video platforms20

0figures bound

cold-chain energy and water

Table 8.2State at baseline
المكوّنالحالةالأدلةالحالة
الحوسبةbiobank-scale association studies emit substantial carbon; software choices matter2122مُبلَّغ عنه
Data growthgenomics projected to be on par with the most demanding data domains20مُبلَّغ عنه
سلسلة التبريدcell therapies are collected, edited and infused; energy not published16Expert input
المياهnot published for laboratories and manufacture21Expert input

الاقترانات

  • ENE ↔ INF facility power
  • ENE → CLI emissions
  • INF → HLT cold-chain continuity

Evidence to bind in 2027

  • sequencing and cold-chain energy
  • laboratory water use

Related editions

  • GLB Global Systems
  • GS-04 Health
  • XT-04 Biotechnology
  • XT-10 Cybersecurity and Advanced Cryptography
  • SR-04 Critical Minerals and Strategic Materials
  • XT-01 Artificial Intelligence and Agentic Systems

8.3Instruments, consumables and supply chain

Sequencing depends on instruments and consumables from a few suppliers, and trade rules changed supply in 2025.

54% fall

Illumina instrument sales in China, Q3 202531

10November 2025

date China lifted its Illumina import ban31

18December 2026

OMB list deadline under BIOSECURE30

Table 8.3State at baseline
المكوّنالحالةالأدلةالحالة
Instrument tradeChina banned Illumina imports in March 2025 and lifted the ban in November 202531مُبلَّغ عنه
Procurement lawBIOSECURE enacted on 18 December 2025; BGI, FGI and MGI covered through the 1260H list30مُبلَّغ عنه
New entrantsa second vendor lists a lower price on its own platform15مُبلَّغ عنه
Reagents and plasticsnot assessed in this edition14Expert input

الاقترانات

  • TRD → INF instruments
  • TRD → DAT data access
  • FIN → INF new platforms

Evidence to bind in 2027

  • consumable supply by country
  • single points of failure by platform

Related editions

  • GLB Global Systems
  • GS-04 Health
  • XT-04 Biotechnology
  • XT-10 Cybersecurity and Advanced Cryptography
  • SR-04 Critical Minerals and Strategic Materials
  • XT-01 Artificial Intelligence and Agentic Systems

8.4Economy, access and workforce

Therapy revenue is rising from a small base, and access is limited by cost and manufacturing capacity. Workforce figures are thin.

42.9USD million

Casgevy revenue, Q1 20266

≈4,200jobs

genetic counsellors in the US, 202533

10%

projected growth, 2025 to 203533

Table 8.4State at baseline
المكوّنالحالةالأدلةالحالة
RevenueUSD 42.9 million in the first quarter of 2026 against USD 14.2 million in 20256مُبلَّغ عنه
الوصولlimited by cost and manufacturing capacity; a Uganda model adapts evidence to local costs78مُبلَّغ عنه
Counselling workforcemedian pay USD 100,040 in May 202533مُبلَّغ عنه
Newborn sequencinga study plans 100,000 babies and screens for more than 200 conditions34مُبلَّغ عنه

الاقترانات

  • FIN → HLT access
  • HLT → FIN payment
  • DAT → FIN data assets

Evidence to bind in 2027

  • patients treated and prices
  • wider workforce

Related editions

  • GLB Global Systems
  • GS-04 Health
  • XT-04 Biotechnology
  • XT-10 Cybersecurity and Advanced Cryptography
  • SR-04 Critical Minerals and Strategic Materials
  • XT-01 Artificial Intelligence and Agentic Systems

8.5Security, data protection and governance watch

Rules decide what reaches patients and who holds genetic data. Heritable editing is judged unacceptable at this time, and approvals for bespoke therapies are being redrawn.

2023first approval

FDA approval of Casgevy, 8 December1

2021WHO framework

published 12 July27

2028application

EU regulation on plants from new genomic techniques applies from 17 July36

Table 8.5State at baseline
المكوّنالحالةالأدلةالحالة
Approvalsfirst CRISPR-based therapy approved; plausible mechanism pathway described15مُبلَّغ عنه
Heritable editingjudged unacceptable at this time by the Third Summit committee28مُبلَّغ عنه
حماية البياناتsale of a large genetic database was approved in bankruptcy in 20253238مُبلَّغ عنه
Plant editingrules in England and the EU2936مُبلَّغ عنه

الاقترانات

  • GOV → HLT approvals
  • GOV → DAT consent
  • GOV → FOO plant rules

Evidence to bind in 2027

  • national rule texts
  • migration of data-protection practice

Related editions

  • GLB Global Systems
  • GS-04 Health
  • XT-04 Biotechnology
  • XT-10 Cybersecurity and Advanced Cryptography
  • SR-04 Critical Minerals and Strategic Materials
  • XT-01 Artificial Intelligence and Agentic Systems

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  2. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  3. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  4. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  5. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  6. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  7. 23Brixi, G. et al., Genome modelling and design across all domains of life with Evo 2, bioRxiv preprint 2025 (abstract read through the Europe PMC record; trained on 9.3 trillion base pairs; not peer reviewed at the time of reading). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03.back
  8. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  9. 20Stephens, Z.D. et al., Big Data: Astronomical or Genomical?, PLOS Biology 2015 (abstract read through the Europe PMC record). Public Library of Science, San Francisco. Observation year 2015. Accessed 2026-11-03.back
  10. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back
  11. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  12. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  13. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  14. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  15. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  16. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03.back
  17. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back
  18. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
  19. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03.back
  20. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  21. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  22. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03.back
  23. 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  24. 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05.back
  25. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back

المنهجية

How the edition was made: methods, the model card, the evidence cut and its age, the acceptance record and the glossary.

15 min read0 figures13 tables21 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

A.1الأساليب

The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.

Table A.1Methods
No.DerivationCalculationالنتيجة
(1)Share of evaluable sickle cell patients free of crises29 ÷ 3097%
(2)Share of evaluable thalassaemia patients transfusion independent32 ÷ 3591%
(3)Year-on-year growth in Casgevy revenue, first quarter42.9 ÷ 14.2about 3.0 times
(4)Evaluable share of treated sickle cell patients30 ÷ 4468%
Table A.2Coupling strength scale (matrix and model card)
Strengthالتعريف
STRONGa disruption in the source system has historically changed the target system’s service or output within one season, in more than one region
MODERATEan effect is documented but buffered or slower
WEAKan effect is plausible but not documented at global scale
Table A.3Status grammar
الوسمالقاعدة
مُبلَّغ عنهvalue as issued by its source, with year
Inferredreasoned from cited evidence; never a measurement
مقدَّرNexus analytical value with stated method
السيناريوconditional on stated assumptions
Expert inputstructured editorial judgement awaiting evidence

A.2Model card, Genomics System Model v0

Model ID
MDL-XT05-GENOMICS · v0.1
الغرض
represent genomics and gene editing as infrastructure coupled to health, compute and energy, trade and supply, finance, workforce and data protection
العائلة
graph-based system of systems
المدخلات
the cited sources of this edition; no proprietary data
المنهج
expert-specified coupling strengths (STRONG · MODERATE · WEAK) from assessments and analogue events
التحقق
none yet, first validation against federation evidence in 2027
عدم اليقين
qualitative; strengths are hypotheses, not measurements
Domain of validity
global scale; not for asset-, site- or country-level use
قابلية إعادة الإنتاج
strength table and sources published in this edition
20couplings

typed in v0

0strong

documented within one season

3moderate

documented, buffered

17weak

plausible, undocumented

A.3The baseline evidence cut

Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.

Cut ID
DC-XTECH-GENOMICS-GLOBAL-2026-B0
النوع
baseline documentary cut
Resolution policy
pinned · as of 30 September 2026
Sources pinned
44 cited sources, each at the edition and access date in the references
Model runs
none at baseline, analytical values are stated with their method
Digest
computed at freeze and recorded in the publication record
Supersedes
nothing, first cut of the series
Superseded by
the 2027 genomics annual cut

النسب

  1. 01

    source edition

  2. 02

    pinned citation

  3. 03

    finding

  4. 04

    page

  5. 05

    publication record

Table A.4From the baseline cut to the federation cut
العنصرBaseline 20262027 global annual
المصادرcited global publications, pinned by editionnational, regional and sector cuts through one graph
Analysisstated methods and editorial estimatestyped analysis specifications
النماذجGenomics System Model v0 specificationmodel runs with receipts
النتائجtwelve baseline findingsfindings re-bound to federation evidence
المراجعةfive passes scheduledfive passes on the exact digest

A.4Evidence age and coverage

A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.

Table A.5Evidence age and coverage
المؤشرمرصودمُصدَروتيرة الإصدارNext release
Phase 3 sickle cell and thalassaemia reports2024NEJM 2024one-offlonger follow-up
FDA approval2023Dec 2023one-offpaediatric label
Patient-specific base editing report2025NEJM 2025one-offfollow-up
Reference genome and pangenome2022 to 2023Science 2022 · Nature 2023دوريpangenome release 2
Biobank genome releases2024 to 2025Nature 2024 · Nature 2025دوريnext releases
Compute footprint studies2021 to 2022Adv Sci 2021 · MBE 2022one-offnew studies
Vertex company report2026page read 2026-11-03فصليnext quarterly report
Illumina trade events2025Feb to Nov 2025لكل حدثcurrent status
Table A.6Coverage by system at baseline
النظامالتغطيةThinnest dimension
TherapiesPARTIALtreatment counts and prices
Data resourcesGOODancestry balance on a common basis
الحوكمةPARTIALnational rule texts
الماليةTHINpayer and price data
الطاقةTHINsequencing and cold-chain energy
SupplyTHINconsumables and reagents
المهاراتTHINworkforce beyond counselling
Agriculture and environmentTHINedited crop and animal data
Table A.7Designed empty states: what is not bound, what would fill it and why
المجالSource that would fill itBlocker
Energy and cooling use of sequencing laboratories and cell-therapy cold chainslaboratories, manufacturers, peer-reviewed footprint studiesnot retrieved; only compute footprints were read2122
NHGRI cost per genome series valuesNHGRI sequencing cost data table13the page shows graphs and a linked Excel table; the values were not read
Independent cost per genome at scaleservice providers, national laboratories, published cost studiesonly vendor list prices were read, and the Ultima page shows both USD 60 and USD 801540
Patients treated with editing therapies, by countrycompany reports, treatment centre registries, regulatorsthe full-year 2025 report gives 64 patients infused worldwide, not by country35; the first quarter 2026 report gave no counts6
Prices paid for editing therapiespayers, health technology assessment bodies, company reportsnot retrieved
Number of people with a sequenced genome worldwidenational programmes, vendors, published talliesno consolidated series found
Ancestry balance of genome datasets on a common basiscohort papers and diversity monitorstwo cohorts and two commentaries read16171819
Sequencer fleet and consumable supply by countrytrade statistics, vendor filingsnot retrieved; only trade events were read31
Text of Regulation (EU) 2026/1388 from the Official JournalOfficial Journal of the European Union36text read; adopted 17 June 2026, published 26 June 2026, applies from 17 July 202836
FDA draft guidance on the plausible mechanism pathwayFDA guidance page37the Federal Register notice of availability was read; the draft guidance text was not read537
Date and terms on which the FDA lifted the 2025 clinical holdscompany and FDA notices39company filings only: holds lifted 27 January 2026 and 2 March 2026; no FDA notice read39
National rules on genetic data, somatic editing and heritable editingstatutes and regulatorsnot retrieved; only the Oviedo text was read41
Genomics workforce beyond genetic counsellorsnational statistics, surveysnot retrieved; only counsellor figures were read33
Capability rungs beyond approvals and planningagencies, clinics, laboratoriesnot reviewed

A.5Evidence cards, two anchor sources

Published in the New England Journal of Medicine in 2024 by Frangoul and colleagues. Phase 3 single-group study. Role: binds HLT-001. Coverage: patients 12 to 35 years of age.

EVD-XT05-001

Exagamglogene autotemcel for severe sickle cell disease2

Published in Science in 2022 by the Telomere-to-Telomere Consortium. One-off assembly. Role: binds DAT-006. Coverage: one human cell line genome.

EVD-XT05-002

The complete sequence of a human genome11

Table A.8Quality dimensions at baseline
DimensionEVD-XT05-001EVD-XT05-002
Completenessone disease; 30 evaluable patientsone genome; all chromosomes except Y gapless
Timelinessinterim analysis at median 19.3 monthssingle release in 2022
Revisionfollow-up reports expectedpangenome release builds on it
Method transparencymethods and end points publishedassembly methods published
External validationpeer reviewpeer review

Evidence cards to follow in 2027

  • Frangoul2: follow-up beyond the median 19.3 months
  • Vertex6: counts of patients treated
  • FDA37: draft guidance text
  • Official Journal36: regulation text

A.6Publication acceptance record

Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.

Table A.9Publication acceptance record
المجموعةالمجالالعناصرالمرورN/Aقيد الانتظار
D1Identity and scope8800
D2Source and data12912
D3Analysis and models12381
D4Findings and claims9801
D5Figures, tables, maps10622
D6Editorial and citations10802
D7Review and approval130013
D8Artefact and design12705
D9Registry and release9009

Publication gate

Conditions met
14 of 23 at evidence close
Blocking problems
none recorded
Open conditions
reviews, approval of the exact digest, deposit, registry pointer

Not applicable at baseline

Model runs
first runs in Q1 2027
الخرائط
plates in Q2 2027
Waivers
لا شيء

A.7Status words

Table A.10The status every value carries
الحالةما يعنيه
مرصودMeasured directly and published by the source.
مُبلَّغ عنهPublished statistics of an official or institutional source.
مُعلَنStated by the body concerned; not independently measured.
مقدَّرA Nexus estimate from cited evidence, with its method in Annex A.
منمذجProduced by a stated model from cited inputs.
InferredReasoned from cited evidence; not measured.
التنبؤA projection by the cited source.
SimulatedA simulation result under stated assumptions.
السيناريوA conditional statement under stated assumptions; never a prediction.
Expert inputExpert judgement, recorded with its basis.
CandidateProposed for a later edition; not yet evidence.
Evidence-quality levels (EQL 1 to 5) grade the source behind a value; they are not a score of the subject.

A.8How the edition is made, released and corrected

Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to Nexus Standards as change proposals and feed the next cut.

خطوةما يحدثالمصدر
01 Evidence arrives from the pillarsFoundry seals observations and indicator series, Universe hands over after-action and scenario findings, and contributions are screened at every gateway, including this site’s.
02 The cut is sealedOn the cut date the evidence is pinned under one identifier, so anyone can rebuild the edition from exactly what it was built on.
03 The edition is assembledThe edition is drafted from its template and content pack. Agents may draft; they never publish and never decide.
04 The keys turnAt the publisher of record the truth key comes first: every value is checked against its source or stated method before the meaning and capital keys turn. No edition moves on until every key has been turned by a named steward.
05 The gate opensA named approver releases one exact digest of the edition; any change after this point is a new version, never a silent edit.
06 Signed and depositedThe PDF, the web edition and the data bundle are signed together with a manifest and an RO-Crate description, and deposited on Zenodo with a concept and a version DOI.
07 Published on its desk’s siteOnly then does the edition show as published on its desk’s Reports site, and the Collection lists it as a part.
08 Corrections go to StandardsMethod and correction findings go to Nexus Standards as change proposals; citations, corrections and new contributions feed the next evidence cut.

A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: Reports governance at GCRI Canada (2026); Zenodo, repository of record for Reports deposits (2026).

Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.

A.9Glossary and abbreviations

Table A.11Series terms
المصطلحالمعنى
Baseline Editionthe inaugural annual edition that fixes the reference state for the series
WEFH+Bwater, energy, food, health and biodiversity, the national nexus core
الترابطa typed dependency through which one system transmits to another
فجوة الحمايةthe share of losses not covered by insurance
Capability ladderLISTED → EXISTS → ADEQUATE → TESTED → DEMONSTRATED
EQLevidence-quality level, 1–5
Evidence cuta frozen resolution of exact sources and versions
⁨NNC⁩ · ⁨NLC⁩ · ⁨NWG⁩National Nexus Consortium · National Leadership Council · National Working Groups
Table A.12Abbreviations used in this edition
AbbreviationExpansion
bpbase pairs
CRISPRclustered regularly interspaced short palindromic repeats
exa-celexagamglogene autotemcel
FDAUS Food and Drug Administration
GWASgenome-wide association study
LNPlipid nanoparticle
NDAANational Defense Authorization Act
NEJMNew England Journal of Medicine
OMBUS Office of Management and Budget
T2TTelomere-to-Telomere
TDTtransfusion-dependent beta-thalassaemia
WHOمنظمة الصحة العالمية

A.10Technical annex

Table A.13Technical annex
البندAnnexالمحتوياتالحالة
A.1Indicator definitionsthe global indicator set, with units and sourcesIN THIS EDITION
A.2Coupling strengthsthe twenty-cell matrix and its rationaleIN THIS EDITION
A.3Scenario specificationSCN-XT05-DLV-01 assumptions and signpostsIN THIS EDITION
A.4Capability placementsrung evidence for fifteen functionsIN THIS EDITION
A.5Model diagnosticsfirst runs and validation2027
A.6Sensitivity analysesinfluence of coupling strengths2027
A.7Cluster notescards for the major sequencing and cell-therapy clusters2027
A.8Review statementspass-by-pass review recordAT RELEASE

A.1 · indicator definition: transfusion independence

Construct
a weighted average haemoglobin level of 9 g per decilitre or higher without red-cell transfusion for at least 12 consecutive months
الوحدة
patients meeting the definition among evaluable patients
المنهج
prespecified interim analysis of an open-label single-group study
المصدر
New England Journal of Medicine 20243
عدم اليقين
95% confidence interval 77 to 98 for the 91% result
الحدود المعروفة
interim analysis; short follow-up; no comparison arm

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  2. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03.back
  3. 13National Human Genome Research Institute (ed.), The Cost of Sequencing a Human Genome (fact sheet page; method notes read; the cost values sit in graphs and a linked table that were not read; page updated 16 May 2023). NHGRI, Bethesda. Observation year 2023. Accessed 2026-11-03.back
  4. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  5. 40Ultima Genomics (ed.), Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris (press release, 24 February 2025, read through a wire copy; USD 0.24 per million reads, enabling the USD 80 genome; vendor evidence, weak). Ultima Genomics, Fremont. Observation year 2025. Accessed 2026-11-05.back
  6. 35Vertex Pharmaceuticals (ed.), Vertex Reports Fourth Quarter and Full Year 2025 Financial Results, Form 8-K exhibit 99.1, 12 February 2026 (company filing read; Casgevy revenue USD 115.8 million in 2025 and USD 10.0 million in 2024; 64 patients infused in 2025; company statement, weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-05.back
  7. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  8. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  9. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  10. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03.back
  11. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03.back
  12. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  13. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05.back
  14. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05.back
  15. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03.back
  16. 39Intellia Therapeutics, Inc. (ed.), Form 8-K of 27 January 2026 and Form 8-K exhibit 99.2 of 2 March 2026 (company filings read; the FDA imposed clinical holds on the MAGNITUDE and MAGNITUDE-2 trials on 29 October 2025 and removed them on 27 January 2026 for MAGNITUDE-2 and on 2 March 2026 for MAGNITUDE, with enhanced liver monitoring; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-05.back
  17. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05.back
  18. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  19. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  20. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  21. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back

Data appendix

The indicator set with its sources, the source registers, the licences of every kind of material and the formats of the edition.

9 min read0 figures8 tables17 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

B.1The indicator set

Table B.1Global baseline indicator set
المؤشرالقيمةالوحدةالسنةالحالةالمصدر
Patients treated with exa-cel, sickle cell study44patients2024مُبلَّغ عنه2
Evaluable patients, sickle cell study30patients2024مُبلَّغ عنه2
Free of severe crises for 12 months or more29patients2024مُبلَّغ عنه2
Median follow-up, sickle cell study19.3أشهر2024مُبلَّغ عنه2
Patients treated with exa-cel, thalassaemia study52patients2024مُبلَّغ عنه3
Transfusion independent, evaluable patients32 of 35patients2024مُبلَّغ عنه3
Base pairs in T2T-CHM133.055billion2022مُبلَّغ عنه11
New sequence in T2T-CHM13≈200million bp2022مُبلَّغ عنه11
Phased assemblies in draft pangenome47assemblies2023مُبلَّغ عنه12
Added sequence in draft pangenome119million bp2023مُبلَّغ عنه12
UK Biobank whole genomes490,640participants2025مُبلَّغ عنه16
All of Us genomes released245,388genomes2024مُبلَّغ عنه17
Casgevy revenue, first quarter 202642.9USD million2026مُبلَّغ عنه6
Casgevy revenue, first quarter 202514.2USD million2025مُبلَّغ عنه6
Genetic counsellor jobs≈4,200jobs2025مُبلَّغ عنه33
Newborn genomes planned in Generation Study100,000babies2026مُبلَّغ عنه34

B.2Global source register

The governed source set behind this edition. Each source keeps its authority, coverage, cadence and role; categories describe origin, not truth.

Domains bound by the register

  • HLT
  • DAT
  • FIN
  • TRD
  • ENE
  • INF
  • GOV
  • FOO
  • BIO
  • AIC
Table B.3Global source register
المصدرالفئةالتغطيةPeriodوتيرة الإصدارالدور
Frangoul et al., NEJM2peer-reviewed journalsickle cell2024one-offtherapy
Locatelli et al., NEJM3peer-reviewed journalthalassaemia2024one-offtherapy
FDA approval notice1national regulatorUS2023one-offapproval
Nurk et al., Science11peer-reviewed journalالمنهجية2022one-offreference genome
UK Biobank and All of Us papers1617peer-reviewed journalUK and US2024 to 2025دوريcohorts
Grealey et al.21peer-reviewed journalالمنهجية2022one-offcompute footprint
Vertex first quarter report6companyglobal2026فصليrevenue
Illumina and Ultima pages1415vendorglobal2026مستمرhardware claims
BIOSECURE and Illumina China summaries3031law firm and trade pressUS and China2025لكل حدثtrade
BLS Occupational Outlook33national statistics officeUS2025سنويworkforce

B.3Regional reading, genomics across ten clusters

Regional plates follow with the regional editions. This page gives the regional reading of genomics infrastructure and exposure in table form and ranks no region.

Table B.4Regional reading, genomics across ten clusters
المنطقةPrincipal hazardsSystems most exposedBaseline evidence
أمريكا الشماليةapprovals; large cohorts; trade and procurement lawtherapies, data, tradeFDA1; All of Us17; BIOSECURE30
أمريكا الجنوبيةearly programmes; access gapsaccessregional evidence (not bound)
أوروباUK Biobank and newborn sequencing; plant-editing rulesdata, rulesUK Biobank16; Generation Study34; Act29
Eurasiaresearch programmes; export controlsresearch, supplyregional evidence (not bound)
الشرق الأوسط وشمال أفريقياtreatment access in several countriesaccessVertex report6
أفريقياcost-effectiveness for sickle cell therapy in Ugandaaccess, costUganda analysis8
جنوب آسياnational genome programmesdata, skillsregional evidence (not bound)
شرق آسياsequencer trade controls; domestic platformssupply, tradeMedTech Dive31
ASEANprogrammes and partnershipsdata, supplyregional evidence (not bound)
Oceania-Pacificresearch programmes; skillsresearch, workforceregional evidence (not bound)

B.4Cluster card: ex vivo editing therapy chain

  • cell therapy
  • cold chain
  • treatment centres
  • single point
Systems in view
cell collection, editing, manufacture, conditioning, infusion
Defining events
approval on 8 December 2023 and a pediatric submission in 202616
الاقترانات
HLT → FIN payment; INF → HLT manufacturing capacity
Capability evidence
authorised treatment centres reported by the company6
الفجوات
patients treated; prices; cold-chain energy
Agenda items
Q-01 · Q-02

A 2026 analysis states that gene therapy access is limited by cost and manufacturing capacity in the United States and globally [7].

ACCESS

Capacity and cost

Vertex reported USD 42.9 million of Casgevy revenue in the first quarter of 2026 and has submitted for children 5 to under 12 [6].

MARKET

Revenue from a small base

A cost-effectiveness analysis compares gene therapy with haploidentical transplantation and standard care [7].

RESPONSE

Alternatives

B.5How countries appear in the genomics edition

Countries enter the genomics edition through the readiness chapters of their own national editions, on one card grammar. They are read against peer distributions and thresholds, never ranked.

Table B.5How countries appear in the genomics edition
Card fieldما يُظهرهالمصدر
WEFH+B stateeach core system against peer distribution bandsnational edition
الاقتراناتthe national dependency matrixnational edition
Risk objectsthe national risk portfolionational edition
Capability rungsthe national capability laddernational edition
Evidence ageoldest and newest source datesnational source register

Editions in the 2026 Baseline programme

26وطني

countries and unions

10regional

clusters

16global

flagship and sector

14strategic

النظم التقارير

20frontier

technology reports

How to read a country card

  • Each system is shown against the distribution of its peers, with thresholds where they exist
  • Couplings and risk objects come from the country’s own national edition
  • Capability rungs record evidence, not a judgement of institutions
  • Evidence age is printed, so older national data are visible as such
Table B.6National Baseline Editions in the 2026 programme
الموجةCountries and unionsالحالة
W0كنداISSUED
W1United States, United Kingdom, France, Germany, Italy, Japan, European Union, SwitzerlandPLANNED
W2Mexico, Brazil, Argentina, Türkiye, Russian Federation, Saudi Arabia, United Arab Emirates, South Africa, Senegal, Kenya, African Union, India, China, Republic of Korea, Indonesia, Singapore, AustraliaPLANNED

B.6التراخيص

Table B.7Licences of each kind of material
المادةالترخيص
النص⁨CC BY 4.0⁩
البياناتon the licence of each source; Nexus tables CC BY 4.0
الأرقامNexus figures CC BY 4.0; third-party as credited
الخرائطboundary source and licence printed on each plate
البيانات الوصفيةCC0 1.0, as Zenodo publishes it
Third-party data, figures and textThe source’s own licence, credited where it is used; never relicensed
Nexus-authored text, tables and figures: CC BY 4.0 (SPDX CC-BY-4.0). Map plates print their boundary source and licence.

B.7Formats and provenance

Table B.8This edition in every format
الصيغةالنوعالحالةما هوالمعرّف
Web editionHTMLفي هذا الموقعDraft in stewardship review; every value resolves to its source.NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
Print editionPDFAt releaseA4 portrait · screen, print and archival PDF, signed with the web edition at release.NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
Indicator dataCSV · JSONفي هذا الموقع16 indicators with unit, year, status and source; the machine-readable copy ships with the evidence bundle at release.NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE data release v1
الأرقامSVG · PNGفي هذا الموقع4 on the web edition: headline figure, figure 1.3, coupling instrument, capability ladder.FIG-XTECH-GENOMICS-GLOBAL-2026-BASELINE-*
SlidesPDFغير مسجّلNo slide deck is recorded for this edition.
موجز الأدلةHTML · PDFغير مسجّلNo evidence brief is recorded for this edition.
Dataset with DOIDataCiteAt releaseConcept and version DOI are minted at deposit; none is recorded yet.

بيان المصدر

Edition pack
The edition’s content pack (JSON), from which the print and web editions are built
Evidence cut
DC-XTECH-GENOMICS-GLOBAL-2026-B0, closed 30 September 2026
قابلية إعادة الإنتاج
sourced values cited; analytical values reproducible from stated parameters
Self-check
14 of 23 at evidence close; a fail on any item blocks release
المراجعة
five passes scheduled before release (in Annex C)
الناشر الرسمي
GCRI for the Nexus Consortium
التصحيحات
Registry correction pathway; upheld corrections are published as notices with a new version

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  3. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03.back
  4. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
  5. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03.back
  6. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03.back
  7. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03.back
  8. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03.back
  9. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03.back
  10. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  11. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03.back
  12. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  13. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back
  14. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03.back
  15. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03.back
  16. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03.back
  17. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03.back

References and record

Every source the edition rests on, the publication record, the corrections log and the open record.

16 min read0 figures1 table0 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

C.144 sources

NR-CIT-1, editor first. A DOI is linked where the source has one; Nexus records carry a UNI once the catalogue allocates it (NS-1).

  1. 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  2. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 7
  3. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 7
  4. 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 5, chapter 6
  5. 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 5, chapter 6, chapter 8
  6. 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
  7. 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
  8. 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 8
  9. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 5, chapter 6, chapter 7
  10. 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 4, chapter 6
  11. 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  12. 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  13. 13National Human Genome Research Institute (ed.), The Cost of Sequencing a Human Genome (fact sheet page; method notes read; the cost values sit in graphs and a linked table that were not read; page updated 16 May 2023). NHGRI, Bethesda. Observation year 2023. Accessed 2026-11-03.
  14. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 7, chapter 8
  15. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 7, chapter 8
  16. 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  17. 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
  18. 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6
  19. 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6
  20. 20Stephens, Z.D. et al., Big Data: Astronomical or Genomical?, PLOS Biology 2015 (abstract read through the Europe PMC record). Public Library of Science, San Francisco. Observation year 2015. Accessed 2026-11-03. Cited in chapter 6, chapter 8
  21. 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
  22. 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6, chapter 8
  23. 23Brixi, G. et al., Genome modelling and design across all domains of life with Evo 2, bioRxiv preprint 2025 (abstract read through the Europe PMC record; trained on 9.3 trillion base pairs; not peer reviewed at the time of reading). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03. Cited in chapter 6, chapter 8
  24. 24Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 2012 (abstract read through the Europe PMC record). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-03. Cited in chapter 4, chapter 6
  25. 25Komor, A.C. et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature 2016 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2016. Accessed 2026-11-03. Cited in chapter 6
  26. 26Anzalone, A.V. et al., Search-and-replace genome editing without double-strand breaks or donor DNA, Nature 2019 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2019. Accessed 2026-11-03. Cited in chapter 6
  27. 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03. Cited in the summary, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  28. 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
  29. 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 6, chapter 8
  30. 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
  31. 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 8
  32. 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 8
  33. 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
  34. 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
  35. 35Vertex Pharmaceuticals (ed.), Vertex Reports Fourth Quarter and Full Year 2025 Financial Results, Form 8-K exhibit 99.1, 12 February 2026 (company filing read; Casgevy revenue USD 115.8 million in 2025 and USD 10.0 million in 2024; 64 patients infused in 2025; company statement, weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-05.
  36. 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05. Cited in chapter 3, chapter 4, chapter 6, chapter 8
  37. 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05. Cited in chapter 4, chapter 6
  38. 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05. Cited in chapter 3, chapter 4, chapter 8
  39. 39Intellia Therapeutics, Inc. (ed.), Form 8-K of 27 January 2026 and Form 8-K exhibit 99.2 of 2 March 2026 (company filings read; the FDA imposed clinical holds on the MAGNITUDE and MAGNITUDE-2 trials on 29 October 2025 and removed them on 27 January 2026 for MAGNITUDE-2 and on 2 March 2026 for MAGNITUDE, with enhanced liver monitoring; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-05. Cited in chapter 2
  40. 40Ultima Genomics (ed.), Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris (press release, 24 February 2025, read through a wire copy; USD 0.24 per million reads, enabling the USD 80 genome; vendor evidence, weak). Ultima Genomics, Fremont. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2
  41. 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05. Cited in chapter 4, chapter 6
  42. 42Lander, E.S. et al., Adopt a moratorium on heritable genome editing, Nature 567 (7747), 165 to 168, 2019 (record read via Crossref). Springer Nature, London. Observation year 2019. Accessed 2026-11-05. Cited in chapter 4, chapter 6
  43. 43International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 409 (6822), 860 to 921, 2001 (record read via Crossref). Springer Nature, London. Observation year 2001. Accessed 2026-11-05. Cited in chapter 6
  44. 44United States Congress (ed.), Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 122 Stat. 881, 21 May 2008 (enrolled text read; prohibits discrimination on the basis of genetic information in health insurance and employment). US Government Publishing Office, Washington. Observation year 2008. Accessed 2026-11-05. Cited in chapter 4, chapter 6

C.2Publication record

النشر

العنوان
Exponential Technology Report 2026: Genomics and Gene Editing, Baseline Edition
السلاسل
Reports · Exponential Technology Series XT-05
الطبعة
Baseline Edition 2026 · inaugural annual
الإصدار
v1.0.0 · draft for stewardship review
Publication ID
NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
إغلاق الأدلة
30 September 2026
Publication date
October 2026
DOI
concept and version DOI at deposit

الناشر

الناشر الرسمي
The Global Centre for Risk and Innovation (GCRI), for the Nexus Consortium
المكان
Toronto
المحرر
Saeed Valadbaygi, Chief Steward and Managing Editor
الأمناء
GCRI · technical truth · GRF · public meaning · GRA · capital meaning
الترخيص
text CC BY 4.0; data on the terms of each source
Copyright
© 2026 GCRI · Nexus Consortium
اللغة
English (en-GB) source edition
Correspondence
Registry correction pathway · editorial office

Colophon

الصيغة
A4 portrait · screen, print and archival PDF
Typefaces
Space Grotesk (display) · Geist (text) · IBM Plex Sans Italic (standfirsts) · IBM Plex Mono (data)
Design standard
Reports Foundational Edition, Volume I, Part VII
إمكانية الوصول
tagged PDF and HTML targets; text alternatives for every figure
الإنتاج
Reports editorial team, GCRI

Release path for this version

Table C.1Release path for this version
خطوةما يحدثمتى
مسودةeditorial self-check complete at evidence closeOctober 2026
Steward reviewfive passes on the exact draft (keys T · M · F · N)Q4 2026
الموافقةpublication authority approves the exact digestbefore release
Depositconcept and version DOI minted; registry pointer setat release
التعاقبthe 2027 genomics edition reports changes against this baseline2027
Current version
v1.0.0 draft, stewardship review
الطبعة السابقة
none, first edition of the series
Next edition
NR-XTECH-GENOMICS-GLOBAL-2027-v1.0.0
Latest version
resolve the concept DOI or the registry record
Correction route
Registry correction pathway
Notice types
erratum · addendum · supersession · withdrawal

C.3سجل التصحيحات

0correction notices. No edition has been released yet, so none can be corrected; the log below lists each edition’s current version.

الطبعةالإصدارالتاريخالحالةالتغيرإشعار
XT-05NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0October 2026مسودةBaseline Edition 2026, inaugural annual edition,لا شيء

Notice types: erratum, addendum, supersession, withdrawal. A correction is a new version with a published notice; the earlier version stays resolvable, and no edition is ever edited in silence.

C.4Open record

This edition’s open record

Publication ID
NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
Desk identifier and series alias
NR-GCRI-XT-05-2026-BASELINE-v1.0.0 · NR-XTC-XT-05-2026-BL
Collection
NR-COL-2026-BASELINE (IsPartOf at deposit)
DOI
Concept and version DOI at deposit, on Zenodo with DataCite metadata
Versions
Each correction is a new version (isNewVersionOf); the concept DOI resolves to the latest
Bundle
RO-Crate 1.2 with CITATION.cff, CodeMeta and PROV-O provenance; a signed manifest
الترخيص
CC BY 4.0 (SPDX CC-BY-4.0) for original material; metadata CC0 1.0

Credit and identity

ORCID
Your iD in the deposit and the contribution record; DataCite can then add the work to your ORCID record
ROR
Your organisation by its ROR identifier, never by a typed name alone
CRediT
Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualisation, Writing, review and editing
الحساب
None needed to contribute; never a password

Find and follow

Search the open indexes for Genomics and Gene Editing; software is cited by its SWHID from Software Heritage, and a quantified scenario run is preregistered on OSF before it is run. Annotation is your choice: Hypothesis opens this page in its own viewer.

Mirrors and harvest

The DOI is canonical. At release each signed bundle is also given an IPFS content identifier and a bloxberg anchor as mirrors; both are listed in the record once they exist. Zenodo exposes every record over OAI-PMH, and reviews and endorsements can arrive through COAR Notify where the repository supports it.

InvenioRDM metadata for a contribution on Genomics and Gene Editing, prefilled from this page
{
  "metadata": {
    "resource_type": {
      "id": "dataset"
    },
    "title": "Evidence on Genomics and Gene Editing for Nexus Reports",
    "publication_date": "YYYY-MM-DD",
    "creators": [
      {
        "person_or_org": {
          "type": "personal",
          "family_name": "Your family name",
          "given_name": "Your given name",
          "identifiers": [
            {
              "scheme": "orcid",
              "identifier": "0000-0000-0000-0000"
            }
          ]
        },
        "affiliations": [
          {
            "id": "ROR identifier of your organisation"
          }
        ]
      }
    ],
    "description": "What it is, where its record is kept and how it bears on Exponential Technology Report 2026: Genomics and Gene Editing.",
    "rights": [
      {
        "id": "cc-by-4.0"
      }
    ],
    "subjects": [
      {
        "subject": "Nexus Reports"
      },
      {
        "subject": "Genomics and Gene Editing"
      },
      {
        "subject": "Exponential Technology Report · XT-05"
      }
    ],
    "related_identifiers": [
      {
        "identifier": "https://therisk.global/nexus-reports/editions/xt-05/",
        "scheme": "url",
        "relation_type": {
          "id": "issupplementto"
        },
        "resource_type": {
          "id": "publication-report"
        }
      }
    ],
    "version": "1.0.0"
  },
  "custom_fields": {},
  "access": {
    "record": "public",
    "files": "public"
  },
  "files": {
    "enabled": true
  },
  "parent": {
    "communities": {
      "default": "nexusreports"
    }
  }
}

C.5Where this edition sits among the six pillars

Foundry seals the evidence and Universe tests it; Reports publishes it; Standards takes its corrections and Academy teaches from it.

  1. F03 Sealed observations and indicator series Foundry Sealed observations and indicator series behind a profile (closeout).
  2. F04 After-action and scenario findings for Universe After-action and scenario findings for chapters 10 and 13 (after action review).
  3. F05 National Portfolio movement for chapter Foundry National Portfolio movement for chapter 11 (after action review).
  4. Applied in editions Standards Nexus Standards: applied in editions.
  5. XT-05 edition Reports Genomics and Gene Editing 2026, published in every format with its sources, citation and corrections.
  6. F06 Method and correction findings as change Standards Method and correction findings as change proposals (correction).
  7. F12 Q4 synthesis informs the next-year Universe Q4 synthesis informs the next-year mandate (renewal).
  8. Taught in the open Academy Risk Academy: taught in the open.

What Foundry and Universe hand to this edition, and what it hands to Standards, Universe and Academy. From the programme spine; XT-05 is a drafted Baseline Edition, so these handoffs run from its first operational quarter.

التسليمBetweenWhat crosses, and when
F03Foundry to ReportsSealed observations and indicator series behind a profile (closeout).
F04Universe to ReportsAfter-action and scenario findings for chapters 10 and 13 (after action review).
F05Foundry to ReportsNational Portfolio movement for chapter 11 (after action review).
RingNexus Standards to ReportsNexus Standards: applied in editions.
F06Reports to Nexus StandardsMethod and correction findings as change proposals (correction).
F12Reports to UniverseQ4 synthesis informs the next-year mandate (renewal).
RingReports to Risk AcademyRisk Academy: taught in the open.
التقاريرساهم

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the GCRI Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

مكتب أدلة النظم في GCRIالتقنيات الأسية

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.